Advanced Search

 

Study ID Status Title Patient Level Data
201709 Recruiting ECHO Analyses From Randomized Controlled Trials of Dabrafenib to Evaluate the Potential for Cardiac Valve Abnormalities
201710 Recruiting Evaluation of Secondary Malignancies in Patients Treated with Dabrafenib in Randomized, Controlled Trials
201711 Recruiting Evaluating Cardiomyopathy and Retinal Pigmented Epithelial Detachments (RPED) in Subjects Treated with GSK1120212 (MEKINIST) as Monotherapy or in Combination with Other Anticancer Therapies
201712 Recruiting Evaluating Cardiomyopathy and Retinal Pigmented Epithelial Detachments (RPED) in Subjects Treated with GSK1120212 (MEKINIST) as Monotherapy or in Combination with Other Anticancer Therapies
201713 Completed An Open-label, Randomized, Single Dose, Three-way Crossover, Six Sequence Pilot Study to Determine the Relative Bioavailability of Candesartan Cilexetil 16mg From Two Candidate Tablet Formulations of GW615775 Relative to One 16mg Tablet of Reference Candesartan Cilexetil in Healthy Adult Human Subjects Under Fasting Conditions
201718 Active, Not Recruiting WEUSKOP6069: Exploratory Cluster Analysis: Relovair COPD exacerbation studies - which patients benefit most from ICS?
201722 Completed Identification and Description of Severe Asthma Patients in a Cross-sectional Study—the IDEAL Study
201724 Active, Not Recruiting HO-14-15325 - Cost of Illness Associated with Early Combination Treatment of BPH in the US
201741 Completed A Phase 1, single-center, randomized, open-label, crossover study to assess the relative bioavailability of Phase III tablet formulation candidates in healthy adult subjects
201749 Recruiting A 24-week treatment, multi-center, randomized, double-blind, double-dummy, parallel group study to compare Umeclidinium/Vilanterol, Umeclidinium, and Salmeterol in subjects with chronic obstructive pulmonary disease (COPD)
201752 Completed A Randomized, Placebo-controlled, Double-Blind (Sponsor Unblind), Repeat Dose, Ascending Cohort, Dose Escalation Phase I Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Epelsiban and its Major Metabolite in Healthy Women Volunteers Following Administration of Repeat Dosing of Epelsiban
201753 Recruiting A 52-week, Phase III, open-label, multi-center study to evaluate efficacy and safety of GSK1278863 in Japanese non-dialysis and peritoneal dialysis subjects with anemia associated with chronic kidney disease
201754 Recruiting A 52-week, Phase III, double-blind, active-controlled, parallel-group, multi-center study to evaluate efficacy and safety of daprodustat compared to darbepoetin alfa in Japanese hemodialysis-dependent subjects with anemia associated with chronic kidney disease who are currently ESA users
201755 Active, not recruiting A Phase IIb, Double-Blind, Placebo-Controlled, Dose-Adaptive, Study of the Efficacy and Safety of GSK3196165 in Combination with Methotrexate Therapy, in Subjects with Active Moderate-Severe Rheumatoid Arthritis Despite Treatment with Methotrexate
201761 Completed PGx7610: Genetic Evaluation of Hepatotoxicity in Pazopanib Studies
201767 Recruiting A Phase 1, Multicompartmental Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers
201769 Completed Exploratory Investigation of Associations between Genome-wide Genetic Variants and Response to Darapladib in the STABILITY (LPL100601) and SOLID-TIMI 52 (SB-480848/033) Trials (PGX7615)
201780 Completed A randomized, open-label, single-period, parallel-group study in healthy subjects to determine the effects of dissolution profile on the pharmacokinetics (via both venous and peripheral micro-samples) of single oral 300 mg doses of Tafenoquine (SB-252263) tablets + 30 mg Tafenoquine stable isotope labelled (SIL) solution
201789 Recruiting A Phase 1/2, Double-Blind, Placebo-Controlled Study of the Pharmacokinetics, Safety and Tolerability of GSK3196165 in Combination with Methotrexate Therapy, in Japanese Subjects with Active Moderate-Severe Rheumatoid Arthritis Despite Treatment with Methotrexate
201793 Recruiting A non-randomized, phase II study of eltrombopag in combination with rabbit anti-thymocyte globulin/cyclosporine A (ATG/CsA) in subjects with moderate or more severe aplastic anemia who have not received prior ATG/anti-lymphocyte globulin (ALG)-based immunosuppressive therapy
201795 Active, Not Recruiting PRJ2376: A cohort study to investigate the prescribing of albiglutide among women of child bearing age
201804 Active, Not Recruiting PRJ2335: An Observational Study of the Risk of Acute Pancreatitis in Subjects Exposed to Albiglutide, Other GLP-1 Agonists and DPP-4 Inhibitors Compared to Other Antidiabetic Agents
201805 Active, Not Recruiting PRJ2331: An Observational Study of the Risk of Malignant Neoplasms and Malignant Neoplasms of Special Interest (Thyroid and Pancreatic Cancer) in Subjects Treated with Albiglutide Compared to Those Treated with Other Antidiabetic Agents
201807 Active, Not Recruiting A Phase 1, Multi-center, Single-masked, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Ophthalmologic Safety and Pharmacodynamics of 300mg Single Doses of Tafenoquine (SB 252263) in Adult Healthy Volunteers
201810 Recruiting A multi-center, randomized, double-blind, placebo controlled, parallel group study to compare cessation versus continuation of long-term mepolizumab treatment in patients with severe eosinophilic asthma (201810)

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.